YBX1通过翻译致癌转录本控制AML细胞竞争
该研究探讨YBX1在急性髓系白血病(AML)中的作用。研究发现YBX1是白血病发生和维持的关键驱动因子,通过将致癌转录本(包括MYC)招募至多聚核糖体链以增强其翻译。遗传失活YBX1可破坏该调控回路,降低白血病细胞增殖并在体内外竞争中胜出,而正常细胞基本不受影响。
要点
- YBX1是AML白血病发生和维持的必需驱动因子。
- YBX1通过将致癌转录本招募至多聚核糖体增强翻译。
- 靶向YBX1可选择性抑制白血病细胞而不影响正常细胞。
核心结论
- YBX1是AML的特异性依赖和治疗靶点,对致癌蛋白表达至关重要。
研究设计与样本
- 基于PubMed来源的AML研究,采用遗传失活YBX1及体外体内功能实验。
主要发现
- YBX1失活破坏致癌转录本翻译,降低白血病细胞增殖。
- 白血病细胞在体外和体内被竞争淘汰,正常细胞基本不受影响。
- YBX1通过招募致癌转录本至多聚核糖体链增强包括MYC的翻译。
临床怎么用
- 靶向YBX1可能选择性削弱恶性细胞竞争而不影响正常细胞。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Persistence of malignant clones is a major determinant of adverse outcome in patients with hematologic malignancies. Despite the fact that the majority of patients with acute myeloid leukemia (AML) achieve complete remission after chemotherapy, a large proportion of them relapse as a result of residual malignant cells. These persistent clones have a competitive advantage and can re-establish disease. Therefore, targeting strategies that specifically diminish cell competition of malignant cells while leaving normal cells unaffected are clearly warranted. Recently, our group identified YBX1 as a mediator of disease persistence in JAK2-mutated myeloproliferative neoplasms. The role of YBX1 in AML, however, remained so far elusive. Here, inactivation of YBX1 confirms its role as an essential driver of leukemia development and maintenance. We identify its ability to amplify the translation of oncogenic transcripts, including MYC, by recruitment to polysomal chains. Genetic inactivation of YBX1 disrupts this regulatory circuit and displaces oncogenic drivers from polysomes, with subsequent depletion of protein levels. As a consequence, leukemia cells show reduced proliferation and are out-competed in vitro and in vivo, while normal cells remain largely unaffected. Collectively, these data establish YBX1 as a specific dependency and therapeutic target in AML that is essential for oncogenic protein expression.
引用
- Perner F, Schnoeder TM, Xiong Y, et al. YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia. 2021. PMID: 34465866. doi:10.1038/s41375-021-01393-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。